FDA Approves Mirdametinib for Adult and Paediatric Patients with NF1 Who Have Symptomatic Plexiform Neurofibromas Not Amenable to Complete Resection By Ogkologos - March 20, 2025 573 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ReNeu study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR This Amazing Woman Can Smell Alzheimer’s, Parkinson’s, and Cancer Years Before... March 22, 2019 Lung cancer screening can’t leave anyone in the UK behind July 27, 2023 Not Old Enough for Breast Cancer, She Demanded a Mammogram Anyway... September 16, 2020 Farmer With Stage IV Cancer Is Too Sick To Harvest Crops... January 23, 2020 Load more HOT NEWS Perguntas frequentes sobre COVID-19 e câncer: respostas para pacientes e sobreviventes 120 years of Cancer Research UK: how science transformed survival rates New on NCI’s Websites for January 2020 Addition of an EGFR Antibody to Fluorouracil/Folinic Acid Maintenance Therapy in...
